InBody continues to work closely with academic researchers on a global scale to develop more in-depth clinical applications of body composition. With our long history in the industry, we provide more than 7,000 research publications. Research title with ★ indicates InBody recommended paper.
Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type
Hepatology | TBW, FFM, SLM, SMM, SMI, BFM, PBF, Protein | Hiroshi Tobita et al. | 2017 | Japan | Current Therapeutic Research
Background Nonalcoholic steatohepatitis (NASH) is an active form of nonalcoholic fatty liver disease. Risk factors for NASH include type 2 diabetes mellitus (T2DM) and obesity. Sodium–glucose cotransporter 2 (SGLT2) inhibitors used to treat T2DM prevent glucose reabsorption in the kidney and increase glucose urinary excretion. Dapagliflozin is a potent, selective SGLT2 inhibitor that reduces hyperglycemia in patients with T2DM and has been demonstrated to reduce some complications associated with NASH in rodent models …
Clinical and pathological features of sarcopenia‐related indices in patients with non‐alcoholic fatty liver disease
Hepatology | SMM, SMI, BFM | Y. Seko et al. | 2019 | Japan | Hepatology Research
Background Sarcopenia is diagnosed with the skeletal muscle index (SMI) or the sarcopenia index (SI). We previously reported that the ratio of skeletal muscle mass to body fat mass (SF ratio) was a novel index of sarcopenia in patients with non‐alcoholic fatty liver disease (NAFLD). The aim of this retrospective study was to evaluate sarcopenia with these indices in patients with NAFLD. Methods One hundred and fifty‐six consecutive patients with biopsy‐proven NAFLD and alanine aminotransferase (ALT)> 40 IU/L were enrolled. Liver function …
Examining the associations among intraocular pressure, hepatic steatosis, and anthropometric parameters
Hepatology | BMI, PBF | Chen et al. | 2019 | Taiwan | Medicine
∗ Correspondence: Wei-Liang Chen, Division of Geriatric Medicine, Department of Family
Medicine, Tri-Service General Hospital, National Defense Medical Center, Number 325, Section
2, Chang-gong Rd, Nei-Hu District, 114, Taipei, Taiwan (e-mail: moc.liamg@8050gnailiew). … Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc … This article has
been cited by other articles in PMC … Emerging evidences had reported the positive relationship
between obesity and intraocular pressure (IOP). The aim of the present study was to investigate …
Long-term branched-chain amino acid supplementation improves glucose tolerance in patients with nonalcoholic steatohepatitis-re
Hepatology | FFM, BFM | Teruki Miyake et al. | 2012 | Japan | Internal Medicine
Branched-chain amino acid (BCAA) supplements have mainly been administered as a nutritional intervention for decompensated liver cirrhosis. Several studies have shown that short-term BCAA supplementation improves insulin and glucose tolerance in patients with liver cirrhosis. However, the long-term effects of BCAA supplementation on glucose tolerance and in patients with nonalcoholic steatohepatitis (NASH)-related liver cirrhosis are unknown. Herein, we report 2 cases of NASH-related liver cirrhosis in which longterm BCAA …
Skeletal muscle mass to visceral fat area ratio is an important determinant affecting hepatic conditions of non-alcoholic fatty
Hepatology | SMM, VFA | Takashi Shida et al. | 2017 | Japan | Journal of Gastroenterology
Background Not only obesity but also sarcopenia is associated with NAFLD. The influence of altered body composition on the pathophysiology of NAFLD has not been fully elucidated. The aim of this study is to determine whether skeletal muscle mass to visceral fat area ratio (SV ratio) affects NAFLD pathophysiology. Methods A total of 472 subjects were enrolled. The association between SV ratio and NAFLD pathophysiological factors was assessed in a cross-sectional nature by stratification analysis. Results When the SV ratio was stratified by …